Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emmaus Life Sciences, Inc.EMMA · Entity 205 | Director · CEO | May 30, 2025 | September 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emmaus Life Sciences, Inc.
Report date May 30, 2025 · Filed September 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stock, $0.001 par valueSEC Table I · non-derivative | IndirectFidelity Roth IRA FBO Willis C. Lee | 229,400 |
Reported balance
After 2025-05-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-05-30 · Purchase · Acquired 70,000 · Balance 229,400 F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.01 to $0.02, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1), footnote (2), footnote (3), footnote (4), footnote (5) and footnote (6). |
| Common stock, $0.001 par valueSEC Table I · non-derivative | IndirectFidelity Roth IRA FBO Willis C. Lee | 275,400 |
Reported balance
After 2025-08-29 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-08-29 · Purchase · Acquired 170,000 · Balance 275,400 F2: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0109 to $0.011, inclusive. |
| Common stock, $0.001 par valueSEC Table I · non-derivative | IndirectFidelity Roth IRA FBO Willis C. Lee | 445,400 |
Reported balance
After 2026-08-25 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-08-25 · Purchase · Acquired 46,000 · Balance 445,400 F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.034 to $0.039, inclusive. |
| Common stock, $0.001 par valueSEC Table I · non-derivative | IndirectFidelity Roth IRA FBO Willis C. Lee | 495,400 |
Reported balance
After 2026-08-27 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2026-08-27 · Purchase · Acquired 50,000 · Balance 495,400 F4: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.044 to $0.051, inclusive. |
| Common stock, $0.001 par valueSEC Table I · non-derivative | IndirectFidelity Roth IRA FBO Willis C. Lee | 590,167 |
Reported balance
After 2026-08-28 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2026-08-28 · Purchase · Acquired 94,767 · Balance 590,167 F5: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.050 to $0.075, inclusive. |
| Common stock, $0.001 par valueSEC Table I · non-derivative | IndirectFidelity Roth IRA FBO Willis C. Lee | 690,167 |
Reported balance
After 2026-08-31 transaction · row 8
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 8 · 2026-08-31 · Purchase · Acquired 100,000 · Balance 690,167 F6: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.046 to $0.05, inclusive. |
| Common stock, $0.001 par valueSEC Table I · non-derivative | Direct | 395,124 |
Reported balance
Holding disclosure · report date 2025-05-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 395,124 |
| Common stock, $0.001 par valueSEC Table I · non-derivative | IndirectFidelity Traditional IRA FBO Willis C. Leeee | 241,194 |
Reported balance
Holding disclosure · report date 2025-05-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 241,194 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.01 to $0.02, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1), footnote (2), footnote (3), footnote (4), footnote (5) and footnote (6).
F2: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.0109 to $0.011, inclusive.
F3: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.034 to $0.039, inclusive.
F4: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.044 to $0.051, inclusive.
F5: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.050 to $0.075, inclusive.
F6: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.046 to $0.05, inclusive.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 17, 2021 Filed Nov 23, 2021 21:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.29 | $1,290.00 |
DisclosureSEC source: 0001209191-21-066428 · doc4.xml · nonDerivative · entry 3 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 120,961 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.24 to $1.30, inclusive. Read SEC document |
| November 16, 2021 Filed Nov 23, 2021 21:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,100 | $1.29 | $2,709.00 |
DisclosureSEC source: 0001209191-21-066428 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 119,961 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.24 to $1.29, inclusive. Read SEC document |
| November 15, 2021 Filed Nov 23, 2021 21:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,600 | $1.24 | $1,984.00 |
DisclosureSEC source: 0001209191-21-066428 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 117,861 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.19 to $1.25, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2), (3), (4) and (5) to this Form 4. Read SEC document |
| September 17, 2021 Filed Sep 18, 2021 00:38 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $1.71 | $855.00 |
DisclosureSEC source: 0001209191-21-056785 · doc4.xml · nonDerivative · entry 3 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 116,261 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.73, inclusive. Read SEC document |
| September 16, 2021 Filed Sep 18, 2021 00:38 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.71 | $1,710.00 |
DisclosureSEC source: 0001209191-21-056785 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 115,761 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.72, inclusive. Read SEC document |
| September 15, 2021 Filed Sep 18, 2021 00:38 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.51 | $3,020.00 |
DisclosureSEC source: 0001209191-21-056785 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 114,761 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.46 to $1.66, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4. Read SEC document |
| September 10, 2021 Filed Sep 10, 2021 22:17 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.72 | $3,440.00 |
DisclosureSEC source: 0001209191-21-055547 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 112,761 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.67 to $1.77, inclusive. Read SEC document |
| September 08, 2021 Filed Sep 10, 2021 22:17 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.70 | $3,400.00 |
DisclosureSEC source: 0001209191-21-055547 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Traditional IRA FBO Willis C. Lee Disclosed balance after: 110,761 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.65 to $1.75, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| August 27, 2021 Filed Aug 27, 2021 21:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.54 | $2,310.00 |
DisclosureSEC source: 0001209191-21-053681 · doc4.xml · nonDerivative · entry 3 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,574 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.49 to $1.57, inclusive. Read SEC document |
| August 26, 2021 Filed Aug 27, 2021 21:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.69 | $1,690.00 |
DisclosureSEC source: 0001209191-21-053681 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,074 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.55 to $1.80, inclusive. Read SEC document |
| August 25, 2021 Filed Aug 27, 2021 21:42 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,400 | $1.51 | $3,624.00 |
DisclosureSEC source: 0001209191-21-053681 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,074 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.44 to $1.55, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 28, 2021 Filed May 28, 2021 22:02 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,900 | $1.57 | $6,123.00 |
DisclosureSEC source: 0001209191-21-036627 · doc4.xml · nonDerivative · entry 3 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,674 F3 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.50 to $1.61, inclusive. Read SEC document |
| May 27, 2021 Filed May 28, 2021 22:02 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,000 | $1.58 | $3,160.00 |
DisclosureSEC source: 0001209191-21-036627 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,774 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.59, inclusive. Read SEC document |
| May 26, 2021 Filed May 28, 2021 22:02 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,700 | $1.53 | $4,131.00 |
DisclosureSEC source: 0001209191-21-036627 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,774 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.59, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 12, 2021 Filed May 12, 2021 22:28 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 13,350 | $1.10 | $14,685.00 |
DisclosureSEC source: 0001209191-21-032183 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,074 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.10 to $1.20, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| May 10, 2021 Filed May 12, 2021 22:28 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.14 | $1,710.00 |
DisclosureSEC source: 0001209191-21-032183 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,724 Read SEC document |
| May 07, 2021 Filed May 7, 2021 21:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,500 | $1.23 | $1,845.00 |
DisclosureSEC source: 0001209191-21-030990 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,224 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.19 to $1.23, inclusive. Read SEC document |
| May 05, 2021 Filed May 7, 2021 21:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,500 | $1.26 | $3,150.00 |
DisclosureSEC source: 0001209191-21-030990 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,724 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.21 to $1.26, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 18:09 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,600 | $0.83 | $1,328.00 |
DisclosureSEC source: 0001209191-20-054870 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,224 Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 18:09 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 6,000 | $0.84 | $5,040.00 |
DisclosureSEC source: 0001209191-20-054870 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,624 Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 18:43 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $1.25 | $5,000.00 |
DisclosureSEC source: 0001209191-20-022059 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 33,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.20 to $1.34, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 18:43 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $1.33 | $665.00 |
DisclosureSEC source: 0001209191-20-022059 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 29,000 Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 18:13 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,300 | $1.05 | $3,465.00 |
DisclosureSEC source: 0001209191-20-021667 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 28,500 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.99 to $1.10, inclusive. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 18:13 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,500 | $1.23 | $4,305.00 |
DisclosureSEC source: 0001209191-20-021667 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 25,200 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.15 to $1.34, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| March 24, 2020 Filed Mar 25, 2020 20:48 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 500 | $1.30 | $650.00 |
DisclosureSEC source: 0001209191-20-021130 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 21,700 Read SEC document |
| March 23, 2020 Filed Mar 25, 2020 20:48 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $1.33 | $1,330.00 |
DisclosureSEC source: 0001209191-20-021130 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 21,200 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.33 to $1.34, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| March 18, 2020 Filed Mar 19, 2020 18:40 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,500 | $1.56 | $5,460.00 |
DisclosureSEC source: 0001209191-20-020227 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 20,200 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.51 to $1.60, inclusive. Read SEC document |
| March 17, 2020 Filed Mar 19, 2020 18:40 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,050 | $1.63 | $4,971.50 |
DisclosureSEC source: 0001209191-20-020227 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 16,700 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.57 to $1.64, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 20:09 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,200 | $1.64 | $1,968.00 |
DisclosureSEC source: 0001209191-20-018467 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 13,650 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.62 to $1.64, inclusive. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:09 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,300 | $1.72 | $2,236.00 |
DisclosureSEC source: 0001209191-20-018467 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 12,450 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.68 to $1.81, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| March 09, 2020 Filed Mar 9, 2020 23:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 9,500 | $1.32 | $12,540.00 |
DisclosureSEC source: 0001209191-20-017496 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 11,150 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.27 to $1.44, inclusive. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 23:10 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,650 | $1.68 | $2,772.00 |
DisclosureSEC source: 0001209191-20-017496 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By FMT CO CUST IRA FBO Willis Lee Disclosed balance after: 1,650 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.60 to $1.70, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| February 13, 2020 Filed Feb 14, 2020 18:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,100 | $1.80 | $1,980.00 |
DisclosureSEC source: 0001209191-20-009517 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,624 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.75 to $1.80, inclusive. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 18:33 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,900 | $1.75 | $3,325.00 |
DisclosureSEC source: 0001209191-20-009517 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,524 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.70 to $1.76, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 17:25 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 2,600 | $1.43 | $3,718.00 |
DisclosureSEC source: 0001209191-20-007815 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,624 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.35 to $1.49, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2). Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 17:25 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,950 | $1.15 | $2,242.50 |
DisclosureSEC source: 0001209191-20-007815 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,024 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.12 to $1.17, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| November 01, 2019 Filed Nov 1, 2019 22:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 800 | $2.98 | $2,384.00 |
DisclosureSEC source: 0001209191-19-054769 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,074 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.89 to $2.99, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| October 31, 2019 Filed Nov 1, 2019 22:19 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $2.90 | $2,900.00 |
DisclosureSEC source: 0001209191-19-054769 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,274 Read SEC document |
| October 18, 2019 Filed Oct 18, 2019 20:03 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 3,890 | $2.79 | $10,853.10 |
DisclosureSEC source: 0001209191-19-053596 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,274 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.75 to $2.80, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1). Read SEC document |
| October 16, 2019 Filed Oct 18, 2019 20:03 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $2.51 | $10,040.00 |
DisclosureSEC source: 0001209191-19-053596 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,384 Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 18:41 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 7,000 | $2.69 | $18,830.00 |
DisclosureSEC source: 0001209191-19-053257 · doc4.xml · nonDerivative · entry 2 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,384 F2 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.32 to $2.76, inclusive. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 18:41 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 4,000 | $2.47 | $9,880.00 |
DisclosureSEC source: 0001209191-19-053257 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,384 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.20 to $2.50, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4. Read SEC document |
| August 27, 2019 Filed Aug 29, 2019 16:40 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 600 | $2.62 | $1,572.00 |
DisclosureSEC source: 0001209191-19-047679 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,384 Read SEC document |
| August 21, 2019 Filed Aug 23, 2019 16:27 UTC | Emmaus Life Sciences, Inc. EMMA · Entity 205 | PurchaseCommon stock, $0.001 par value | 1,000 | $3.35 | $3,350.00 |
DisclosureSEC source: 0001209191-19-047235 · doc4.xml · nonDerivative · entry 1 LEE WILLIS C · CIK 0001517775 · Director · Vice Chairman & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,784 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.